Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
TCRX
#3152
TScan Therapeutics, Inc. Common Stock
1.0
6
-3.64%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
-3.64%
Variazione Mensile
-4.50%
Variazione di 6 mesi
-43.32%
Variazione Annuale
-48.29%
Chiusura Precedente
1.1
0
Open
1.0
6
Bid
Ask
Low
1.0
6
High
1.0
6
Volume
6
Mercati
Mercato Azionario Statunitense
Salute
TCRX
Open full chart
Financials
Overview
Estratto Conto
Statistics
Dividends
Quarterly
Annual
Value
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
18.76 M
19.08 M
43.61 M
52.31 M
—
Valuation ratios
Enterprise value
-53.51 M
-4.54 M
662.44 M
324.42 M
602.51 M
Price to earnings ratio
—
-0.62
-4.2
-2.67
-6.93
Price to sales ratio
—
3.04
17.8
120.9
212.92
Price to cash flow ratio
—
0.62
6.1
3.07
7.61
Price to book ratio
—
0.41
2.48
1.41
2.08
Enterprise value to EBITDA ratio
—
—
—
—
—
Profitability ratios
Return on assets %
0.26
0.33
0.33
0.34
0.46
Return on equity %
0.3
0.67
0.59
0.53
0.77
Return on invested capital %
687.92
585.8
537.56
686.88
—
Gross margin %
100
100
100
100
400
Operating margin %
479.65
492.32
444
4 787.68
9 922.53
EBITDA margin %
—
—
—
—
—
Net margin %
479.49
489.26
423.86
4 527.66
9 580.2
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
7.76
7.17
6.51
8.14
30.19
Inventory turnover
—
—
—
—
—
Asset turnover
0.05
0.07
0.09
0.01
0.03
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
—
0.15
0.1
0.09
0.41
Long term debt to total equity ratio
—
0.29
0.18
0.13
0.69
Per share metrics
Operating cash flow per share
—
2.77
0.94
0.99
1.04
EBIT per share
—
—
—
—
—
EBITDA per share
—
—
—
—
—
Total debt per share
—
—
—
—
—
Cash per share
—
4.99
2.93
2.59
7.63
Net current asset value per share
—
5.16
2.96
2.61
7.73
Tangible book value per share
—
4.13
2.3
2.15
6.24
Working capital per share
—
4.44
2.51
2.29
6.72
Book value per share
—
4.13
2.3
2.15
6.24
Notizie
TScan completa l’arruolamento nella coorte dello studio, riceve l’autorizzazione FDA
TScan completes enrollment in trial cohort, receives FDA clearance
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Tscan Therapeutics mantiene rating Neutrale da BTIG dopo evento ASH
Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event
TScan to host KOL event discussing updated ALLOHA trial data
Morgan Stanley declassa le azioni di Tscan Therapeutics per ritardi nei trial
Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials